The BCCNM board on Dec. 20, 2023, rescinded the limit related to amphetamines and other designated drugs in the
Nurse Practitioner Scope of Practice Standards, Limits and Conditions: Prescribing Drugs. This change takes effect immediately and will permit NPs to prescribe amphetamines such as Adderall to their adult clients.
Nurse practitioners who treat clients with attention deficit hyperactivity disorder (ADHD) could previously prescribe amphetamines (e.g., Adderall) to pediatric clients, but were unable to prescribe those same drugs to adults due to a restriction in the federal Food and Drug Regulations (Section G.04.001) related to amphetamines and other designated drugs and a corresponding limit in BCCNM's
Nurse Practitioner Scope of Practice Standards, Limits and Conditions: Prescribing Drugs.
On Dec. 1, 2023, BCCNM was notified of an exemption under the Controlled Drugs and Substances Act (CDSA) titled
Subsection 56(1) Class Exemption for Certain Practitioners to Administer Designated Drugs for Therapeutic Use. This exemption supported BCCNM to rescind its limit on amphetamines and other designated drugs.